Bladder Cancer

Mitomycin C Use is Beneficial

BERLIN—Long-term prophylaxis with mitomycin C (MMC) significantly decreases the risk of tumor recurrence compared with short-term prophylaxis with MMC or bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer, according to German researchers.

Cystoscopy Superior to Urine Test

The sensitivity of the UroVysion DNA urinary test is too low to be considered an alternative to cystoscopy in the follow-up of patients with superficial bladder cancer, according to researchers in Sweden.

When to Use Intravesical Therapies

Bladder cancer is projected to be the fourth most common cancer diagnosed in 2007 and the eighth most common cause of cancer-specific death in men, according to the American Cancer Society. Approximately 70% of bladder tumors present as non-muscle invasive (NMI) disease and 10%-20% will progress to muscle invasion.

Bladder Cancer Drug R&D Falls Short

A principal reason for poor outcomes among bladder cancer patients is metastatic disease during follow-up. With currently available drugs, metastatic disease to other solid organs is only curable in less than 10% of patients, according to Virginia urologist Dan Theodorescu, MD, PhD.

Next post in News